Florida judge dismisses Novo Nordisk lawsuit over compounded semaglutide, but company plans to file again
Novo Nordisk is planning to file an amended complaint against a Florida compounding pharmacy it claims is illegally making a version of its blockbuster weight-loss and diabetes drugs, after the judge granted a motion to dismiss the case last week.
In July, Novo filed a series of lawsuits against compounding pharmacies, including three in Florida and one in Tennessee. The drugmaker accused the them of illegally selling drugs that they claim contain semaglutide, the primary ingredient in Novo’s blockbusters Wegovy, Ozempic and Rybelsus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.